The Society for Immunotherapy of Cancer (SITC) hosted Session 107d during the 39th Annual Meeting & Pre-Conference Programs on Friday, November 8, 2024. Available here are the presentation slides and video from “Session 107d: NK Cells and Innate Immunity” as permitted by presenters.
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
Eric Vivier, DVM, PhD – Aix Marseille University
Natural Killer (NK) cells and Type 1 Innate Lymphoid Cells (ILCs) play a critical role in the innate immune response by detecting and destroying neoplastic cells independently of prior antigen exposure. Their therapeutic modulation represents an emerging frontier in cancer immunotherapy.
In this session at the SITC conference Dr. Marco Colonna will provide a detailed overview of ILCs, highlighting their potential in cancer immunotherapy. Dr. Rezvani will present on the engineering of NK cells, discussing the latest strategies and preclinical evidence that underscore the translation of this strategy to the clinic. Dr. Eric Vivier will present on the application of NK cell multi-specific engagers, focusing on their design, mechanism of action, and their evolving role in the targeted treatment of cancer. Each presentation aims not only to educate but also to encourage dialogue on how these innovations can be best integrated and optimized within current clinical frameworks.
To view the entire program schedule (including presenter permission to post) please click here.
01:38:49